Catalyst Biosciences to Present at the Piper Sandler 33rd Annual Virtual Healthcare Conference
November 22 2021 - 8:00AM
Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced that
members of its executive management team will participate in a
fireside chat at the Piper Sandler 33rd Annual Virtual Healthcare
Conference, being held November 29-December 2, 2021.
The fireside chat will be available on-demand for registered
attendees via the Piper Sandler conference site beginning Monday,
November 22, 2021 at 10:00 am ET until the end of the conference on
Thursday, December 2, 2021. To access the fireside chat, please
click here. An archived webcast will be available for 90 days on
the Events and Presentations section of the Company’s website.
About Catalyst Biosciences, the Protease Medicines
companyCatalyst is a research and clinical development
biopharmaceutical company focused on developing protease
therapeutics to address unmet medical needs in disorders of the
complement system. Proteases are natural regulators of this
biological system. We engineer proteases to create improved or
novel molecules to treat diseases that result from dysregulation of
the complement cascade. Our complement pipeline consists of a
preclinical C3-degrader program licensed to Biogen for dry
age-related macular degeneration (dAMD), an improved Complement
Factor I protease CB 4332 for SQ replacement therapy in patients
with Complement Factor I (CFI) deficiency and proteases from our
ProTUNE™ C3b/C4b degrader and ImmunoTUNE™ C3a/C5a degrader
platforms designed to target specific disorders of the complement
or inflammatory pathways.
Forward-Looking StatementsThis press release
contains forward-looking statements that involve substantial risks
and uncertainties. Forward-looking statements include, without
limitation, those regarding swiftly moving forward with clinical
development of CB 4332, the continued generation of candidates from
the protease platform that will either be licensed or
self-developed, reduction of burn rate, the potential that
complement will open opportunities in multiple disease settings,
submitting an IND for CB 4332, announcing a development candidate
from our ProTUNE™ platform that leverages our knowledge of CFI, and
successfully completing the transfer of CBIO supported activities
to Biogen for CB 2782-PEG, as well as statements about the benefits
of our protease engineering platform. Actual results or events
could differ materially from the plans, intentions, expectations,
and projections disclosed in the forward-looking statements.
Various important factors could cause actual results or events to
differ materially, including, but not limited to, the risk that
clinical trials and preclinical studies may be delayed as a result
of COVID-19, competitive products, and other factors, that Biogen
could terminate our agreement for the development of CB 2782-PEG,
that the Company's complement degraders are not yet in human
clinical trials and will require additional manufacturing
validation and preclinical testing before entering human clinical
trials, that the Company may need to raise additional capital, and
other risks described in the "Risk Factors" section of the
Company's Annual Report on Form 10-K filed with the Securities and
Exchange Commission (the "SEC") on March 4, 2021, the Quarterly
Report on Form 10-Q filed with the SEC on November 12, 2021, and in
other filings filed from time to time with the SEC. The Company
does not assume any obligation to update any forward-looking
statements, except as required by law.
Contact:
Ana KaporCatalyst Biosciences, Inc.investors@catbio.com
Catalyst Biosciences (NASDAQ:CBIO)
Historical Stock Chart
From Aug 2024 to Sep 2024
Catalyst Biosciences (NASDAQ:CBIO)
Historical Stock Chart
From Sep 2023 to Sep 2024